BIONTECH - BNTX STOCK NEWS

BioNTech (Nasdaq: BNTX) announced a conference call on July 1, 2020, at 11:00 a.m. EDT to discuss preliminary data from its ongoing Phase 1/2 trial of an mRNA-based vaccine against SARS-CoV-2. The firm continues to leverage its expertise in mRNA vaccine development and manufacturing to advance multiple vaccine candidates for infectious diseases and an extensive oncology pipeline. The call can be accessed via phone or webcast, with a replay available for 30 days post-event.

BioNTech (BNTX) and Pfizer announced preliminary results from a Phase 1/2 clinical trial of their mRNA vaccine candidate BNT162b1 against SARS-CoV-2. In 45 subjects, those receiving 10 µg and 30 µg doses exhibited significantly elevated RBD-binding IgG antibody levels and neutralizing antibody titers, outperforming convalescent sera. No serious adverse events were reported. If successful, a global Phase 2b/3 trial could start in July 2020, with plans to manufacture up to 100 million doses by the end of 2020 and over 1.2 billion by 2021, pending regulatory approval.

BioNTech (BNTX) announced a private investment totaling USD 250 million from Temasek and other accredited investors. The investment will include approximately USD 139 million in ordinary shares and USD 112 million in mandatory convertible notes, which carry a 4.5% annual coupon. Investors will receive 2,595,996 ordinary shares subject to a 180-day lock-up. The deal is expected to close in early to mid-August 2020, pending customary conditions. BioNTech focuses on patient-specific immunotherapies for cancer and infectious diseases.

BioNTech has secured a €100 million debt financing agreement from the European Investment Bank (EIB) to advance its BNT162 COVID-19 vaccine initiative and enhance manufacturing capacity in Europe. This funding is disbursed in two tranches linked to specific milestones, supported by European Commission initiatives including Horizon 2020 and the European Fund for Strategic Investments. BioNTech leads with multiple BNT162 vaccine candidates in clinical trials, aiming to expedite global supply amidst the pandemic.

BioNTech SE (BNTX) provided an update on its COVID-19 vaccine program BNT162, now in Phase 1/2 trials in Europe and the U.S. The first cohorts have been dosed, with the trial aiming to determine the optimal dose and evaluate safety and immunogenicity. As of March 31, 2020, BioNTech reported cash equivalents of €451.6 million and a net loss of €53.4 million for Q1 2020. The company is on track to fund BNT162 development through partnerships, estimating approximately €300 million in net cash for 2020. A conference call is scheduled for May 12, 2020.

BioNTech (Nasdaq: BNTX) has completed the acquisition of Neon Therapeutics, Inc. (Nasdaq: NTGN) in an all-stock deal, announced initially on January 16, 2020. The newly formed subsidiary, BioNTech US Inc., will be based in Cambridge, Massachusetts, serving as BioNTech’s U.S. headquarters. As of May 7, 2020, Neon’s common stock will cease trading. This acquisition represents a strategic move to enhance BioNTech's immunotherapy portfolio, particularly in mRNA-based therapies, further solidifying its position in the biopharmaceutical market.

On May 5, 2020, Pfizer and BioNTech announced the initiation of Phase 1/2 clinical trials for their BNT162 COVID-19 vaccine in the U.S., following successful dosing in Germany. The trial aims to assess the vaccine's safety and optimal dosage with a target of enrolling 360 healthy participants aged 18-85. Pfizer plans to expedite vaccine manufacturing, aiming for millions of doses in 2020 and hundreds of millions in 2021. The joint effort will commercialize the vaccine globally upon regulatory approval, excluding China, where BioNTech collaborates with Fosun Pharma.

BioNTech SE (Nasdaq: BNTX) will announce its first quarter 2020 financial results on May 12, 2020, at 08:00 a.m. EDT. The company will host a conference call and webcast to present these results alongside a corporate update. The presentation materials will be available online, and a replay will be accessible for 30 days post-call. BioNTech focuses on novel immunotherapies for cancer and serious diseases, utilizing advanced drug platforms. The company collaborates with major pharmaceutical partners, enhancing its biopharmaceutical development capabilities.